NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
8.17M
Enterprise Value 3
-4.21M
Trailing P/E
N/A
Forward P/E 1
-0.47
PEG Ratio (5 yr expected) 1
0.01
Price/Sales (ttm)
N/A
Price/Book (mrq)
0.51
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
0.25

Trading Information

Stock Price History

Beta (3Y Monthly) 4.24
52-Week Change 3-81.84%
S&P500 52-Week Change 314.45%
52 Week High 35.2100
52 Week Low 30.4000
50-Day Moving Average 30.5975
200-Day Moving Average 31.0622

Share Statistics

Avg Vol (3 month) 376.73k
Avg Vol (10 day) 351.57k
Shares Outstanding 512.97M
Float 7.21M
% Held by Insiders 18.40%
% Held by Institutions 147.50%
Shares Short (Oct 31, 2019) 461.42k
Short Ratio (Oct 31, 2019) 40.44
Short % of Float (Oct 31, 2019) 40.71%
Short % of Shares Outstanding (Oct 31, 2019) 40.47%
Shares Short (prior month Sep 30, 2019) 428.79k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 29/1
Last Split Date 3May 11, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-51.72%
Return on Equity (ttm)-90.79%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -17.03M
Net Income Avi to Common (ttm)-17.04M
Diluted EPS (ttm)-1.7020
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)13.7M
Total Cash Per Share (mrq)1.06
Total Debt (mrq)409k
Total Debt/Equity (mrq)2.55
Current Ratio (mrq)7.79
Book Value Per Share (mrq)1.24

Cash Flow Statement

Operating Cash Flow (ttm)-15.23M
Levered Free Cash Flow (ttm)-8M